Case-Based Roundtable Meetings Spotlight: November 1, 2022

During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.

At a live event discussing the case of a man, aged 75 years, with metastatic castration-resistant prostate cancer, Rana McKay, MD, focused on the makeup and results of the pivotal phase 4 CARD and phase 3 VISION studies.

During a Targeted Oncology case-based roundtable event, Joel Neal, MD, PhD, and Leah Backhus, MD, MPH, discussed adjuvant therapies including chemotherapy, immunotherapy, and targeted therapy for patients with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Raajit K. Rampal, MD, PhD, discussed recommendations and data on the use of JAK inhibitors to treat patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Bradley J. Monk, MD, discussed recommendations for managing toxicity and dosing of PARP inhibitors as primary maintenance for ovarian cancer.

During a Targeted Oncology case-based roundtable event, Omid Hamid, MD, discussed the data supporting the use of hedgehog pathway inhibitors and immunotherapies for skin cancers.

During a Targeted Oncology case-based event, Alan H. Bryce, MD, discussed decision-making for treating a patient with non-metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Adam Binder, MD, discussed trials supporting triplet and quadruplet regimens along with autologous stem cell transplant.

During a Targeted Oncology case-based roundtable event, Jason Westin, MD, discussed recent clinical trial data for patients with relapsed/refractory diffuse B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Ravi Salgia, MD, PhD, discussed with participants their approach to molecular testing and treatment of a patient diagnosed with non–small cell lung cancer.